LACTOLOGY FOUNDATION

The ATC group A02BA51 covers cimetidine combinations, mainly with sucralfate or pirenzepine, with distinct toxicological and lactation-relevant profiles for each partner drug.

Pharmacological overview

Cimetidine is a histamine H2‑receptor antagonist that inhibits gastric acid secretion, used for peptic ulcer disease, reflux and other acid‑related disorders. ATC code A02BA51 designates fixed or co‑administered combinations in which cimetidine is combined with other gastrointestinal agents, most notably sucralfate or pirenzepine, to enhance antiulcer efficacy or mucosal protection.

Sucralfate is a basic aluminum salt of sucrose octasulfate that forms a viscous, adhesive complex with ulcer bases and inflamed mucosa, providing local protection with negligible systemic absorption. Pirenzepine is a selective antimuscarinic acting predominantly on gastric M1 receptors, reducing basal and stimulated acid secretion while exhibiting typical anticholinergic systemic effects.

Cimetidine–sucralfate combinations

Cimetidine–sucralfate regimens are used in stress ulcer prophylaxis and peptic ulcer therapy, with sucralfate providing topical cytoprotection and cimetidine systemic acid suppression. In controlled studies of stress bleeding prophylaxis, combinations of pirenzepine plus sucralfate or pirenzepine plus cimetidine were at least comparable in preventing bleeding, illustrating that cimetidine and sucralfate can be combined within multimodal regimens.

Pharmacokinetically, concurrent administration of cimetidine and sucralfate can reduce the absorption and effectiveness of cimetidine due to adsorption/complexation by sucralfate in the gastrointestinal tract. Clinical guidance therefore advises against simultaneous dosing; if unavoidable, cimetidine should be given at least 2 hours before sucralfate to limit this interaction.

From a toxicology standpoint, the systemic safety of the combination is largely driven by cimetidine exposure and the aluminum content of sucralfate, with the latter minimally absorbed in patients with normal renal function. Usual cimetidine adverse effects (CNS symptoms, endocrine effects such as reversible gynecomastia at high doses, and extensive CYP-mediated drug interactions) remain relevant and may be more clinically significant than any systemic effect of sucralfate.

During pregnancy, cimetidine–sucralfate combinations are classified as FDA pregnancy category B, reflecting the absence of evidence of teratogenicity in humans and animals for these regimens. Toxicologically, this supports cautious use when clearly indicated, particularly in women with complicated ulcer disease or high stress‑ulcer risk.

In lactation, cimetidine–sucralfate combinations are assigned Toxylactation category I, indicating compatibility with breastfeeding and low expected risk to the nursing infant. Sucralfate is virtually not absorbed and does not enter breast milk in clinically relevant amounts, while cimetidine is excreted into milk but at doses that are unlikely to cause adverse effects in most infants.

Cimetidine–pirenzepine combinations

Cimetidine–pirenzepine combinations aim for additive acid suppression by combining H2 blockade and selective antimuscarinic inhibition of gastric secretion. In volunteers with duodenal ulcer disease in remission, low‑dose cimetidine plus pirenzepine provided significantly better 24‑hour intragastric pH control than full‑dose monotherapy with either agent alone, especially in the post‑prandial period.

The toxicology of this combination is shaped by both cimetidine’s interaction and endocrine profile and pirenzepine’s anticholinergic burden. Typical antimuscarinic effects such as dry mouth, constipation, blurred vision, and potential tachycardia can be expected, and they may be dose‑limiting in sensitive adults or those with pre‑existing cardiovascular or ophthalmic disease.

In pregnancy, cimetidine–pirenzepine combinations are classified as FDA pregnancy category D, reflecting evidence or suspicion of fetal risk related to the anticholinergic component, even though pirenzepine itself has not demonstrated teratogenicity in standard experimental models. Use in pregnant women would therefore be restricted to situations where potential maternal benefit clearly outweighs fetal risk.

During lactation, pirenzepine’s potent anticholinergic effect defines the toxicological profile and renders the combination absolutely incompatible with breastfeeding according to the Toxylact system, which places cimetidine–pirenzepine regimens in category IV. Even in the absence of robust pharmacokinetic data in human milk, the risk of anticholinergic adverse effects in the nursing infant (e.g. ileus, urinary retention, sedation) is considered unacceptable when safer alternatives are available.

Lactation data for cimetidine

Cimetidine is excreted into breast milk, with studies indicating that a fully breastfed infant receives approximately 6–7% of the maternal weight‑adjusted dose at usual therapeutic exposures. Clinical experience and observational data have not identified adverse effects in breastfed infants, especially when they are older than two months and have normal renal and hepatic function.

Authoritative lactation resources and expert reviews consider cimetidine compatible with breastfeeding, though some practice guidelines now regard it as a less preferred H2‑blocker compared with famotidine or nizatidine because of higher relative milk levels and its extensive drug‑interaction profile. When cimetidine is necessary in a breastfeeding woman, standard‑dose monotherapy or combination with non‑absorbed agents such as sucralfate is acceptable, provided the infant is monitored for rare signs of gastrointestinal disturbance or sedation.

By contrast, addition of a strongly anticholinergic agent such as pirenzepine is considered contraindicated in lactation, and alternative regimens (other H2 blockers or proton pump inhibitors) are strongly preferred. This distinction underpins the Toxylact classification difference between cimetidine–sucralfate (category I) and cimetidine–pirenzepine (category IV) combinations.

Practical clinical recommendations

In breastfeeding women with acid‑related disorders, non‑pharmacological measures and antacids or alginates should be tried first, followed by well‑studied H2 blockers or proton pump inhibitors where needed. If cimetidine is used and combinations are considered, pairing with sucralfate is toxicologically acceptable during lactation, provided doses are staggered (cimetidine at least 2 hours before sucralfate) to avoid reduced efficacy.

Cimetidine–pirenzepine combinations should be avoided in breastfeeding due to the high anticholinergic risk to the infant and the availability of safer acid‑suppressive options. During pregnancy, cimetidine–sucralfate (category B) may be considered when clearly indicated, whereas cimetidine–pirenzepine (category D) should be reserved for exceptional cases where the maternal benefit justifies the documented fetal risk.